Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503771 | 0.89 | KMT2A (0.52) | CNR2CA1CA2POLBTDP1 | |
| SCHEMBL5510059 | 0.89 | KMT2A (0.52) | CNR2CA1CA2POLBTDP1 | |
| SCHEMBL5508077 | 0.82 | ALDH1A1 (0.50) | CNR2CA1CA2TDP1L3MBTL1 | |
| SCHEMBL11346990 | 0.82 | ALDH1A1 (0.50) | CNR2CA1CA2TDP1L3MBTL1 | |
| SCHEMBL11349061 | 0.82 | ALDH1A1 (0.50) | CNR2CA1CA2TDP1L3MBTL1 | |
| SCHEMBL5504001 | 0.82 | ALDH1A1 (0.50) | CNR2CA1CA2TDP1L3MBTL1 | |
| SCHEMBL5508282 | 0.81 | ALDH1A1 (0.51) | CNR2CA1CA2TDP1L3MBTL1 | |
| SCHEMBL11354624 | 0.81 | CA1 (0.48) | CA1CA2POLBTDP1L3MBTL1 | |
| SCHEMBL11346245 | 0.78 | CA1 (0.45) | CA1CA2POLBL3MBTL1HTT | |
| SCHEMBL5504049 | 0.78 | CA1 (0.48) | CA1CA2POLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101146770-A | 2-phenyl indoles as prostaglandin D2 receptor antagonists | AVENTIS PHARMA INC (US) | 2008-03-19 | — | — | CN | disclosed |
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1844011-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006081343-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265278-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, CYSLTR2 | CNR2 22/4885CA1 3015/4885CA2 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.